						1	1					
		Computation of C	Leiling Price based on Aug 2015 Dat	a under Para	a 6 of DPCO 2013							
						Number of C	ompani	es consist	ting of Market Sh	nare of 1% & Ab	ove	1
	30.8	Thiamine	Tablet 100 mg	Per Tablet					for price calcula			206.08
						PTR under Co	onsidera	ition				3.72
						% Reduction	with co	mpared t	o Highest Price (average)		17.21%
						Reduction as	per Mo	nopoly co	ondition			0.64
						PTR after Red	duction					3.08
						Add : 16% Re	tailer N	1argin				0.49
						Ceiling Price	(withou	t local tax	(es) (wef. 10.3.20	016)		3.57
						WPI Reduction	on wef 1	.4.2016 (@ -2.7105%			0.10
			S.O. 619(E) dated 26.02.2015			Final Ceiling	Price (w	ithout loc	cal taxes) (wef. 0	1.4.2016 or dat	e of notification, whichever is later)	3.47
			Ceiling Price as per NLEM 2011	4.32	Per Tablet							
			Derived Ceiling PTR	3.72								
A. Li	t of Item (Inder consideration							TOTAL MAT	2,06,14,798	100.00	%
S.	Unique	Composition as per NLEM	पैक विवरण	छाप	कंपनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
No.	No. as		Pack Description	BRAND	Company		Size					Considered
	per											(Rs.)
	NLEM											
1	30.8	VITAMIN B1 PLAIN (WITH ADDITIVES) A11E13	BENALGIS 100 MG TABLET 10	BENALGIS	FRANCO INDIAN PHARMACEUTICALS PVT LTD	100 MG	10	TABLET	50.17	2,06,07,735	99.97	% 3.72
		VITAMIN B1 PLAIN (WITH ADDITIVES) A11E13	THYMINE 100 MG TABLET 10	THYMINE	SYNOKEM PHARMACEUTICALS LTD	100 MG	10	TABLET	35.00	7,063	0.03	%
B. Co	mputation	of Average rate of Reduction under Monopoly										
		S. No.	Drug(s)	Strength	Description	Route of		S.O. nun	nber & date			Reduction
						Administrati						with reference
						on/ Dosage						to the highest
						Form &						PTR under
						packsize/pa						NLEM 2015 (%)
						cking, if any						
		1	Thiamine	Injection		Injection		1561 (E)	dated 27.4.2016	5		17.21
				100 mg/ml								
<u> </u>						-				1		
								Average	Reduction			17.21

		Computation of Ceili	ng Price based on Aug 2015 Data u	nder Para 6 c	of DPCO 2013							
						Number of Co	ompani	es consist	ting of Market SI	hare of 1% & /	Above	1
	6.4.3.2.2	Nevirapine	Oral Liquid 50mg/5ml	Per ML		Sum of MAT	value co	nsidered	d for price calcula	ation (in Lakhs	5)	0.25
			, 5			PTR under Co				,	,	0.78
						% Reduction	with co	mpared t	to Highest Price (average)		12.75%
						Reduction as	per Mo	nopoly c	ondition			0.10
						PTR after Rec	duction					0.68
						Add : 16% Re	tailer N	largin				0.11
						Ceiling Price	(withou	t local ta	xes) (wef. 10.3.2	016)		0.79
						WPI Reduction						0.02
			S.O. 619(E) dated 26.02.2015			Final Ceiling I	Price (w	ithout lo	cal taxes) (wef. 0	1.4.2016 or d	ate of notification, whichever is later)	0.77
			Ceiling Price as per NLEM 2011	1.08	Per ML							
			Derived Ceiling PTR	0.93								
A. Lis	st of Item U	Inder consideration							TOTAL MAT	25,323		
S.	Unique	Composition as per	पैक विवरण	छाप	कंपनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
No.	No. as	NLEM	Pack Description	BRAND	Company		Size					Considered
	per											(Rs.)
	NLEM											
1	6.4.3.2.2	NEVIRAPINE J5B7	NEVIMUNE 50 MG SUSPENSION 10	NEVIMUNE	CIPLA LTD.	50 MG	100	ML	78.40	25,323	100.00%	0.78
		L										
B. Co			duction under Monopoly						L			
		S. No.	Drug(s)	Strength	Description	Route of		S.O. nun	nber & date			Reduction
						Administrati						with reference
						on/ Dosage						to the highest
						Form &						PTR under
						packsize/pa						NLEM 2015 (%)
						cking, if any						
		1	Nevirapine	Tablet 200		Tablet		1253(E)	dated 29.3.2016			12.7
				mg				(- /				
	1				1	 	1	-	Reduction			12.75

$\overline{}$												
		Computation of Ceilin	g Price based on Aug 2015 Data und	er Para 6 of I	OPCO 2013							
						Number of C	Compan	ies consis	ting of Market S	hare of 1% & Above		1
	30.1	Ascorbic acid (Vitamin C)	Tablet 100 mg	Per Tablet						lation (in Lakhs)		37.41
		, ,				PTR under C	onsider	ation		, ,		0.11926
						% Reduction	with co	ompared t	o Highest Price	(average)		11.90%
						Reduction as	s per M	onopoly c	ondition			0.01419
						PTR after Re	duction					0.10507
						Add : 16% Re	etailer N	√argin				0.01681
						Ceiling Price	(withou	ut local ta	xes) (wef. 10.3.2	2016)		0.12188
						WPI Reducti	on wef	1.4.2016	@ -2.7105%			0.00330
			S.O. 836(E) dated 25.3.2015			Final Ceiling	Price (v	vithout lo	cal taxes) (wef.	01.4.2016 or date of r	notification, whichever is later)	0.11858
			Ceiling Price as per NLEM 2011	0.19	Per Tablet							
			Derived Ceiling PTR	0.16								
A. I	ist of Item	Under consideration							TOTAL MAT	37,40,828		
s.	Unique	Composition as per NLEM	पैक विवरण	छाप	कंपनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
No.	No. as		Pack Description	BRAND	Company		Size					Considered
	per											(Rs.)
	NLEM											
1	30.1	PLAIN VITAMIN C (INCLUDING VITAMIN C SALTS) A11X31	CELIN 100 MG TABLET 1000	CELIN	GLAXOSMITHKLINE PHARMACEUTICALS LTD.	100 MG	1000	TABLET	119.26	37,40,828	100.009	% 0.11926
В. С	omputatio	n of Average rate of Reduction under Monopoly										
		S. No.	Drug(s)	Strength	Description	Route of		S.O. nur	nber & date			Reduction
						Administrat						with
						ion/						reference to
						Dosage						the highest
						Form &						PTR under
						packsize/pa						NLEM 2015 (%)
						cking, if any						
			1 Ascorbic acid (Vitamin C)	500mg		tablet		Propose	d in current 39	th meeting		11.90
				tablet								1
1				1				Average	Reduction			11.90

		Computation of C	eiling Price based on Aug 2015 Da	ta under Para	6 of DPCO 2013								
						Number of C	ompani	es consist	ting of Market S	hare of 1% & A	bove	1	
	23.3	Neostigmine	Tablet 15 mg	Per Tablet		Sum of MAT value considered for price calculation (in Lakhs)							
						PTR under Co	onsidera	ation				4.12	
						% Reduction	with co	mpared t	o Highest Price	(average)		7.01%	
					Reduction as	per Mo	nopoly c	ondition			0.29		
						PTR after Re	duction					3.83	
						Add : 16% Re						0.61	
									kes) (wef. 10.3.2	2016)		4.44	
						WPI Reduction	on wef :	1.4.2016 (@ -2.7105%			0.12	
			S.O. 619(E) dated 26.02.2015			Final Ceiling	Price (w	ithout lo	cal taxes) (wef. (01.4.2016 or da	te of notification, whichever is later)	4.32	
			Ceiling Price as per NLEM 2011	5.11	Per Tablet								
			Derived Ceiling PTR	4.41									
A. L	st of Item I	Under consideration							TOTAL MAT	1,17,30,918			
S.	Unique	Composition as per	पैक विवरण	छाप	कंपनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit	
No.	No. as	NLEM	Pack Description	BRAND	Company		Size					Considered	
	per											(Rs.)	
	NLEM												
1	23.3	NEOSTIGMINE N7C10	TILSTIGMIN 15 MG TABLET 10	TILSTIGMIN	TABLETS INDIA LTD	15 MG	10	TABLET	41.22	1,17,30,918	100.00%	4.12	
B. C		n of Average rate of Redu	- ' <i>'</i>										
		S. No.	Drug(s)	Strength	Description	Route of		S.O. nun	nber & date			Reduction	
						Administrati	i					with reference	
						on/ Dosage						to the highest	
						Form &						PTR under	
						packsize/pa						NLEM 2015 (%)	
						cking, if any							
				1									
		1	Neostigmine	Injection		Injection		Propose	d in current 391	th meeting		7.01	
				0.5 mg/ml			<u> </u>			T			
								Average	Reduction			7.01	

	l											
		Compu	tation of Ceiling Price based on Aug 201	L5 Data und	er Para 6 of DPCO 2013							
					1	Number of Co	ompani	es cons	sisting of Marke	t Share of 1%	& Above	1
	12.2.2	Amiodarone	Injection 50 mg/ml	Per ML					red for price cald			20.41
						PTR under Co	nsidera	ation				18.71
						% Reduction	with co	mpare	d to Highest Pric	e (average)		13.82%
						Reduction as	per Mo	nopoly	y condition			2.59
						PTR after Rec	duction					16.12
						Add : 16% Re	tailer N	1argin				2.58
									taxes) (wef. 10.	3.2016)		18.70
									.6 @ -2.7105%			0.51
			S.O. 619(E) dated 26.02.2015			Final Ceiling F	Price (w	ithout	local taxes) (we	f. 01.4.2016 c	r date of notification, whichever is later)	18.19
			Ceiling Price as per NLEM 2011		Per ML							
			Derived Ceiling PTR	19.76								
A. L	st of Item	Under consideration							TOTAL MAT	20,40,805		
S.		Composition as per	पैक विवरण	छाप	कंपनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
No.	No. as	NLEM	Pack Description	BRAND	Company		Size					Considered
	per											(Rs.)
	NLEM											
1			RITEBEAT 50 MG INJECTION 2 ML		TORRENT PHARMACEUTICALS LTD.	50 MG		ML	53.94	1,22,552	6.01%	
		AMIODARONE C1B3	RITEBEAT IV 50 MG INJECTION 3 ML	RITEBEAT	TORRENT PHARMACEUTICALS LTD.	50 MG	3	ML	52.95	19,18,253	93.99%	17.65
			<u> </u>									
B. C			luction under Monopoly									
		S. No.	Drug(s)	Strength	Description	Route of		S.O. n	umber & date			Reduction
						Administrati						with reference
						on/ Dosage						to the highest
						Form &						PTR under
						packsize/pa						NLEM 2015 (%)
						cking, if any						
-												
		1	Amiodarone	200 mg		Tablet		1819	(E) dated 18.5.2	016		9.52
<u> </u>				Tablet				24051	=> .			45 15
		2	Amiodarone	100 mg		Tablet		2195(E) dated 23.6.20)16		18.12
-				Tablet		1		<u> </u>		1		40
						1		Avera	ge Reduction			13.82

					1	1		T				1
			Communitation of Calling Bridge has a day of	2045 D-4	C F DDCO 2042							
-			Computation of Ceiling Price based on A	ug 2015 Data	a under Para 6 of DPCO 2013	No contract of C			tion of Name of the	h f 40/ 0, A h		+
			0 11: 11:00 /5 1							hare of 1% & Above		171.10
	6.4.1.1	Acyclovir	Oral liquid 400 mg/5 ml	Per ML					for price calcula	ation (in Lakns)		171.18
						PTR under Co			1			1.21
									to Highest Price (average)		13.91%
						Reduction as			ondition			0.17
						PTR after Red						1.04
						Add : 16% Re						0.17
									xes) (wef. 10.3.2	016)		1.21
						WPI Reduction						0.03
			S.O. 619(E) dated 26.02.2015			Final Ceiling	Price (w	vithout lo	cal taxes) (wef. 0	1.4.2016 or date of r	notification, whichever is later)	1.18
			Ceiling Price as per NLEM 2011		Per ML							
			Derived Ceiling PTR	1.25								
A. List	of Item Und	der consideration							TOTAL MAT	1,71,17,929		
S. No.	Unique	Composition as	पैक विवरण	छाप	कं पनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
	No. as	per NLEM	Pack Description	BRAND	Company		Size					Considered
	per											(Rs.)
	NLEM											
1	6.4.1.1	ACICLOVIR J5A4	ZOVIRAX 400 MG SUSPENSION 100 ML	ZOVIRAX	GLAXOSMITHKLINE PHARMACEUTICALS LTD.	400 MG	100	ML	121.01	1,71,17,929	100.009	% 1.21
B. Com	putation o	f Average rate of Re	duction under Monopoly									
			Drug(s)	Strength	Description	Route of		S.O. nu	mber & date			Reduction
						Administrat						with reference
						ion/						to the highest
						Dosage						PTR under
						Form &						NLEM 2015 (%)
						packsize/pa						
						cking, if any						
						cking, it ally						
		1	Acyclovir	Tablet 200		tablet	-	2105/E)	dated 23.6.2016	:		13.62
		1	Acyclovii			tablet		2133(L)	uateu 23.0.2010	,		13.02
				mg								
		2	Acyclovir	Tablet 400		tablet		2195(E)	dated 23.6.2016	5		5.15
				mg								
		_					<u> </u>	L				
		3	Acyclovir	Powder for		Powder for		Propose	ed in current 391	n meeting		28.25
				Injection		Injection						
				250 mg								
		-	A social social	Daniel au C		Daniel and	1	B	. d t	d 41		0.55
		4	Acyclovir	Powder for		Powder for		Propose	ed in current 391	n meeting		8.63
				Injection		Injection						
			1		T. Control of the Con		1	1				1
				500 mg								
				500 mg								
				500 mg								

				1	1				1			
		Comput	ation of Ceiling Price based on Aug	2015 Data	under Para 6 of DPCO 2013							
						Number of C	ompani	es consi	isting of Market	Share of 1% &	a Above	1
	12.1.3	Diltiazem	Injection 5 mg/ml	Per ML					ed for price calcu			56.81
			y			PTR under Co						2.66
						% Reduction	with co	mpared	to Highest Price	e (average)		2.73%
						Reduction as		_		Ì		0.07
						PTR after Red						2.59
						Add : 16% Re	tailer N	/largin				0.41
									axes) (wef. 10.3.	.2016)		3.00
						WPI Reduction				1		0.08
			S.O. 619(E) dated 26.02.2015			Final Ceiling	Price (w	ithout l	ocal taxes) (wef.	01.4.2016 or	date of notification, whichever is later)	2.92
			Ceiling Price as per NLEM 2011	3.33	Per ML		,		1		,	
			Derived Ceiling PTR	2.87								
A. L	ist of Item I	Under consideration							TOTAL MAT	56,81,061		
S.	Unique	Composition as per	पैक विवरण	छाप	कंपनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per
No.	No. as	NLEM	Pack Description	BRAND	Company		Size					Unit
	per NLEM		·									Considered
	ľ											(Rs.)
1	12.1.3	DILTIAZEM C8A6	DILZEM IV 5 MG INJECTION 5 ML	DILZEM	TORRENT PHARMACEUTICALS LTD.	5 MG	5	ML	13.28	56,81,061	100.00%	
B. C	omputatio	n of Average rate of R	eduction under Monopoly									
		S. No.	Drug(s)	Strength	Description	Route of		S.O. nu	umber & date	•		Reduction
					-	Administrati						with
						on/ Dosage						reference to
						Form &						the highest
						packsize/pa						PTR under
						cking, if any						NLEM 2015
						,						(%)
		1	Diltiazem	SR Tablet		tablet		1253(E) dated 29.3.201	16		3.28
				90 mg				,	•			
		_								_		
		2	Diltiazem	Tablet 30		tablet		2195(E	a) dated 23.6.201	16		2.48
				mg								
		3	Diltiazem	Tablet 60		tablet		2195(F	a) dated 23.6.201	16		2.43
				mg					,	-		
								Averag	ge Reduction			2.73